ROR 억제제 : 대상 환자층, 경쟁 구도 및 시장 예측(2036년)

Key Highlights:

• Receptor Tyrosine Kinases (RTKs) are transmembrane proteins that relay growth-factor signals to sustain a diverse set of biological responses from cell proliferation to apoptosis and differentiation. A distinct subfamily of RTKs comprises Wnt receptors, such as receptor tyrosine kinase orphan-like receptors 1 and 2 (ROR1/2).
• ROR1 is highly expressed in a variety of cancers, including hematological cancers such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and solid tumors (ovarian, breast, prostate, lung, melanoma, colorectal cancers, and others).
• ROR1 is a highly expressed cell surface antigen present on many aggressive solid tumors, including approximately 60% of patients with Triple-negative Breast Cancer (TNBC) and 40% of patients with Non-small Cell Lung Cancer (NSCLC).
• Several key companies, including Merck (Zilovertamab vedotin), Novalgen (NVG-111, NVG-222, NVG-333), BioAtla (Ozuriftamab vedotin), CStone Pharmaceuticals (CS5001), and others, are involved in developing ROR inhibitors.

DelveInsight's "ROR Inhibitors - Target Population, Competitive Landscape, and Market Forecast - 2036" report delivers an in-depth understanding of the ROR inhibitors, historical and competitive landscape as well as the ROR inhibitors market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The ROR inhibitors market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM ROR inhibitors market size from 2022 to 2036. The report also covers current ROR inhibitors treatment practices/algorithms and unmet medical needs to curate the best opportunities and assess the market's potential.

Geography Covered:

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2022-2036

ROR Inhibitors Understanding and Treatment Algorithm

ROR Inhibitors Overview

The ROR-family proteins, ROR1 and ROR2, act as receptors or co-receptors for non-canonical Wnt ligands such as Wnt5a, thereby regulating cell polarity, migration, proliferation, and differentiation that are required for proper developmental morphogenesis and tissue-/organo-genesis. In the RORs subfamily, there are three members: RORa, RORB, and ROR?, encoded by RORA, RORB, and RORC, respectively. All of these receptors are transcription factors that are ligand-dependent.

ROR1 and ROR2 are tyrosine kinase-like orphan receptors that play critical roles in embryogenesis. Aberrant expression of ROR1 has been observed in a range of cancers compared to its limited expression in healthy adult tissue, which makes it a candidate target for treating these cancers. ROR1 has been demonstrated to play an oncogenic role in many tumor types and has been broadly linked with cell proliferation, stemness, Epithelial-mesenchymal Transition (EMT), and other metastatic abilities. In contrast, the role of ROR2 in carcinogenesis remains controversial, as it acts as either a tumor suppressor or a tumor promoter in different cancers.

The ROR inhibitor family of proteins includes ROR1 and ROR2, receptor tyrosine kinases. ROR1 is especially interesting to pharmacologists as it has only been observed in cancerous and embryonic cells, and never in healthy adult tissue. This makes it a strong therapeutic target for the treatment of several types of cancer. ROR1 and ROR2 are implicated in age-related diseases, including tissue fibrosis, atherosclerosis (or arteriosclerosis), neurodegenerative diseases, and cancers.

ROR Inhibitors Epidemiology

The ROR inhibitors epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented as total cases of selected indication for ROR inhibitors, total eligible patient pool for ROR inhibitors in selected indication, total treated cases in selected indication for ROR inhibitors in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), and the United Kingdom, and Japan from 2022 to 2036.

• According to DelveInsight's estimates, the incident cases in the 7MM for DLBCL were ~78,000 in 2024. Among EU4 and the UK, Germany accounted for the highest incident cases of DLBCL.
• Within the 7MM, the US emerged as the leading contributor to HNSCC cases, accounting for nearly 43% of the total burden.
• MCL is a rare subtype of B-cell non-Hodgkin lymphoma (NHL) with an annual incidence of one case per 200,000 people. MCL comprises around 5% of all NHLs.
• As per DelveInsight's estimates, the incident cases in the US for NSCLC were ~207,000 in 2025. Cases of NSCLC were higher among those aged >=65 years than those aged <65 years.
• According to the American Cancer Society (2026), CLL comprises 25-30% of total leukemia's in the US. There were approximately 23,000 new CLL cases in the year of 2026.
• According to Freedman et al., (2025), the incidence of MCL increases with age and appears to be rising in the US. Median age at diagnosis is 68 years. Approximately three-quarters of patients with MCL are male.

ROR Inhibitors Drug Chapters

The drug chapter segment of the ROR inhibitors report encloses a detailed analysis of ROR inhibitors in different stages of development. It also helps understand the ROR inhibitors' clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Emerging Drugs

Zilovertamab Vedotin (MK-2140): Merck

Zilovertamab vedotin is an investigational antibody-drug conjugate (ADC) that targets ROR1. ROR1 is a transmembrane protein that is overexpressed in multiple hematologic malignancies. Merck is committed to research with zilovertamab vedotin across B-cell malignancies and is establishing a robust program of clinical trials under the name waveLINE.

According to the JP Morgan Healthcare Conference data readout, the Phase II/III waveLINE-003 trial for first line DLBCL is anticipated between 2026 and 2027, while the Phase III waveLINE-010 trial for 2L+ DLBCL is projected beyond 2028.

Ozuriftamab vedotin (BA3021): BioAtla/Bristol-Myers Squibb

Ozuriftamab vedotin is a Conditionally Active Biologic (CAB) anti-ROR2 ADC consisting of a CAB anti-ROR2 humanized IgG1 monoclonal antibody conjugated to monomethyl auristatin E (MMAE) using a cleavable linker. Ozuriftamab vedotin has shown promising overall response rates in SCCHN, and the FDA has granted FTD for ozuriftamab vedotin in recurrent or metastatic SCCHN. The Company is re-evaluating the timing and scope of its clinical development programs, including the appropriate timeline and pacing of additional enrollment in the Phase I study of BA3182, as well as the timeline to commence a Phase III Study for ozuriftamab vedotin (Oz-V) (CAB-ROR2-ADC) in 2L+ oropharyngeal squamous cell carcinoma (OPSCC). While the Company remains focused on conducting the ongoing Phase I study and is committed to its clinical development programs, there can be no assurances that clinical development of its programs will not be limited or delayed pending the outcome of the strategic process.

In December 2025, BioAtla and GATC announced a SPV transaction to advance ozuriftamab vedotin (Oz-V) (CAB-ROR2-ADC) in a Phase III Study in 2L+ oropharyngeal squamous cell carcinoma (OPSCC).

CS5001: CStone Pharmaceuticals

CS5001 is a clinical-stage ADC targeting ROR1. CS5001 has been uniquely designed with proprietary tumor-cleavable linker and pyrrolobenzodiazepine prodrug. In October 2020, CStone signed a licensing agreement with LigaChem Biosciences for the development and commercialization of CS5001.

In March 2026, the company announced that the global Phase Ib multicenter trial of CS5001 (ROR1 ADC) is being advanced rapidly and efficiently in Australia and China, with its R&D progress ranking among the top two globally. In combination with R-CHOP as a first-line treatment for DLBCL (at doses of 50-90 μg/kg), the CR rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination cohort for later-line DLBCL has also shown favorable safety and a high ORR.

ROR Inhibitors Market Outlook

ROR1/2 are putative druggable targets increasing in significance in translational oncology. Increasing evidence emerging from functional and structural studies points toward Wnt-binding receptor pseudokinases having a key role in regulating functional processes in normal and pathological conditions, despite their lack of catalytic activity. Overexpression of ROR1 and ROR2 has been detected in numerous cancers. For instance, in hematological cancers, the reactivation of ROR1 signaling in CLL, MCL, and B-ALL is linked to advanced disease stage and activation of AKT signaling in ROR1-high positive cells. ROR2 expression was also shown to activate AKT signaling in multiple myeloma.

ROR1 is considered an ideal druggable target for oncology because of its demonstrated pro-tumourigenic actions, cancer-specific expression, cell surface expression, and availability of drugs that can regulate ROR1 action. ROR2 is also under clinical evaluation as a drug target, with several clinical trials in progress, including one of Bioatla BA3021, a CAB ROR2-targeted ADC.

Several key companies, including Merck (Zilovertamab Vedotin), Octernal Therapeutics (ONCT-808), Novalgen (NVG-111, NVG-222, NVG-333), BioAtla (Ozuriftamab vedotin), CStone Pharmaceuticals (CS5001), and others, are involved in developing ROR inhibitors.

ROR Inhibitor Drugs Uptake

This section focuses on the uptake rate of potential approved and emerging ROR inhibitors expected to be launched in the market during 2026-2036.

ROR Inhibitors Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I. It also analyzes key players involved in developing targeted therapeutics.

The presence of numerous drugs at different stages is expected to generate immense opportunities for the ROR inhibitors market growth over the forecasted period.

Pipeline development activities

The report covers information on collaborations, acquisitions and mergers, licensing, and patent details for ROR inhibitors emerging therapies.

The increasing strategic collaborations among major market players to enhance the growth of their pipeline products are anticipated to drive market expansion.

KOL Views

To keep up with current and future market trends, we take Industry Experts' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry experts were contacted for insights on ROR's evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along challenges related to accessibility.

DelveInsight's analysts connected with 25+ KOLs to gather insights; however, interviews were conducted with 10+ KOLs in the 7MM. Centers such as Penn Medicine's Hematologic Malignancies Translational Center of Excellence, UC Davis Comprehensive Cancer Center, University of Texas MD Anderson Cancer Center, etc. were contacted.

Their opinion helps understand and validate current and emerging therapy treatment patterns or ROR inhibitors market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Market Access and Reimbursement

Reimbursement may be referred to as the negotiation of a price between a manufacturer and payer that allows the manufacturer access to the market. It is provided to reduce the high costs and make the essential drugs affordable. Health Technology Assessment (HTA) plays an important role in reimbursement decision-making and recommending the use of a drug. These recommendations vary widely throughout the seven major markets, even for the same drug.

In the US healthcare system, both Public and Private health insurance coverage are included. Also, Medicare and Medicaid are the largest government-funded programs in the US. The major healthcare programs including Medicare, Medicaid, the Children's Health Insurance Program (CHIP), and the state and federal health insurance marketplaces are overseen by the Centers for Medicare & Medicaid Services (CMS). Other than these, Pharmacy Benefit Managers (PBMs), and third-party organizations that provide services, and educational programs to aid patients are also present.

The report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Key Updates on ROR Inhibitors

• In March 2026, CStone Pharmaceuticals announced that the global Phase Ib multicenter trial of CS5001 (ROR1 ADC) is being advanced rapidly and efficiently in Australia and China, with its R&D progress ranking among the top two globally. In combination with R-CHOP as a first-line treatment for DLBCL (at doses of 50-90 μg/kg), the CR rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination cohort for later-line DLBCL has also shown favorable safety and a high ORR.

In December 2025, BioAtla and GATC announced a SPV transaction to advance ozuriftamab vedotin (Oz-V) (CAB-ROR2-ADC) in a Phase III Study in 2L+ oropharyngeal squamous cell carcinoma (OPSCC).

In June 2025, Merck presented the data from the Phase II/III waveLINE-003 study evaluating zilovertamab vedotin, an investigational ADC that targets ROR1, plus standard of care as a treatment for patients with relapsed or refractory DLBCL at the ASCO 2025 annual meeting.

• In February 2025, Merck announced the initiation of waveLINE-010, a pivotal Phase III clinical trial evaluating zilovertamab vedotin in combination with rituximab plus cyclophosphamide, doxorubicin, and prednisone (R-CHP) compared to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) alone, for the treatment of patients with previously untreated DLBCL.
• According to BioAlta's Q1 2025 financial highlights, the company is utilizing FTD for additional discussions with the US FDA in treatment-refractory, metastatic HPV-positive SCCHN for guidance on a proposed Phase III study.
• In May 2025, BioAlta announced a poster presentation of the Phase II trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated SCCHN at ASCO 2025.

Scope of the Report:

• The report covers a segment of key events, an executive summary, and a descriptive overview of the ROR Inhibitor, explaining its mechanism, and emerging ROR inhibitors.
• Comprehensive insight into the competitive landscape, and forecasts, the future growth potential of treatment rate, drug uptake, and drug information have been provided.
• Additionally, an all-inclusive account of the current and emerging therapies and the elaborative profiles of late-stage and prominent therapies will impact the current landscape.
• A detailed review of the ROR Inhibitor market, historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach.
• The report provides an edge while developing business strategies, by understanding trends, through SWOT analysis, expert insights/KOL views, and treatment preferences that help shape and drive the 7MM ROR Inhibitor market.

ROR Inhibitors Report Insights

• ROR Inhibitors Targeted Patient Pool
• Therapeutic Approaches
• ROR Inhibitors Pipeline Analysis
• ROR Inhibitors Market Size and Trends
• Existing and Future Market Opportunity

ROR Inhibitors Report Key Strengths

• 11-Year Forecast
• The 7MM Coverage
• Key Cross Competition
• Drug Uptake and Key Market Forecast Assumptions

ROR Inhibitors Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness
• Qualitative Analysis (SWOT)
• Conjoint Analysis

Key Questions:

• What was the ROR inhibitor total market size, the market size by therapies, market share (%) distribution, and what would it look like in 2036? What are the contributing factors for this growth?
• Which drug is going to be the largest contributor in 2036?
• Which is the most lucrative market for ROR Inhibitors?
• What are the pricing variations among different geographies?
• What are the risks, burdens, and unmet needs of treatment for ROR inhibitors? What will be the growth opportunities across the 7MM for the patient population of ROR inhibitors?
• What are the key factors hampering the growth of the ROR inhibitors market?
• What key designations have been granted to ROR inhibitors?
• Patient acceptability in terms of preferred therapy options as per real-world scenarios?

Reasons to buy:

• The report will help develop business strategies by understanding the latest trends and changing dynamics driving the ROR inhibitors market.
• Understand the existing market opportunities in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• Detailed analysis and ranking of indication-wise current and emerging therapies under the conjoint analysis section to provide visibility around leading indications.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of expensive off-label therapies, and patient assistance programs.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.

Table of Contents

1. Key Insights

2. Report Introduction

3. Executive Summary of ROR Inhibitors

4. Key Events

5. Market Forecast Methodology

6. ROR Inhibitors Market Overview at a Glance in the 7MM

• 6.1. Market Share (%) Distribution by Therapies in 2025
• 6.2. Market Share (%) Distribution by Therapies in 2036

7. ROR Inhibitors: Background and Overview

• 7.1. Introduction
• 7.2. Treatment

8. Target Patient Pool

• 8.1. Key Findings
• 8.2. Assumptions and Rationale: 7MM
• 8.3. Epidemiology Scenario in the 7MM
• 8.4. Total Cases in Selected Indications for ROR Inhibitors in the 7MM
• 8.5. Total Eligible Patient Pool for ROR Inhibitors in Selected Indications in the 7MM
• 8.6. Total Treated Cases in Selected Indications for ROR Inhibitors in the 7MM

9. Emerging Therapies

• 9.1. Key Competitors
• 9.2. Zilovertamab Vedotin (MK-2140): Merck
  • 9.2.1. Product Description
  • 9.2.2. Other Developmental Activities
  • 9.2.3. Clinical Development
  • 9.2.4. Clinical Trials Information
  • 9.2.5. Safety and Efficacy
  • 9.2.6. Analyst Views

10. ROR Inhibitors: Seven Major Market Analysis

• 10.1. Key Findings
• 10.2. Market Outlook
• 10.3. Conjoint Analysis
• 10.4. Key Market Forecast Assumptions
  • 10.4.1. Cost Assumptions and Rebates
  • 10.4.2. Pricing Trends
  • 10.4.3. Analogue Assessment
  • 10.4.4. Launch Year and Therapy Uptakes
• 10.5. Total Market Size of ROR Inhibitors in the 7MM
• 10.6. Market Size of ROR Inhibitors by Indication in the 7MM
• 10.7. Market Size of ROR Inhibitors by Therapies in the 7MM
• 10.8. The United States Market Size
  • 10.8.1. Market Size of ROR Inhibitors by Indication in the United States
  • 10.8.2. Market Size of ROR Inhibitors by Therapies in the United States
• 10.9. EU4 and the UK Market Size
  • 10.9.1. Market Size of ROR Inhibitors by Indication in EU4 and the UK
  • 10.9.2. Market Size of ROR Inhibitors by Therapies in EU4 and the UK
• 10.1. Japan Market Size
  • 10.10.1. Market Size of ROR Inhibitors by Indication in Japan
  • 10.10.2. Market Size of ROR Inhibitors by Therapies in Japan

11. Market Access and Reimbursement

12. SWOT Analysis

13. KOL Views

14. Unmet Needs

15. Appendix

• 15.1. Bibliography
• 15.2. Report Methodology

16. DelveInsight Capabilities

17. Disclaimer

18. About DelveInsight